To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Resource Library
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
ITP
International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
May 4 - 7, 2024
-
Atlanta, GA, USA
International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
May 4 - 7, 2024
-
Atlanta, GA, USA
Posters
- Burden of illness for adults living with primary chronic immune thrombocytopenia in the United States
- Real-world treatment patterns in adults living with primary chronic immune thrombocytopenia in the United States
- Characterization of adult patients with primary chronic immune thrombocytopenia using US administrative claims data
International Society on Thrombosis and Haemostasias (ISTH)
June 23 - 27, 2023
-
Montreal, Canada
International Society on Thrombosis and Haemostasias (ISTH)
June 23 - 27, 2023
-
Montreal, Canada
- PRESENTATION: Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial dostarlimab
- PRESENTATION: Biomarker correlates of response in patients with advanced Myxoid/Round Cell Liposarcoma (MRCLS) treated with NY-ES0-1 TCR T cells (Letetresgene autolueucel)
European Hematology Association (EHA)
June 7 - 10, 2023
-
Frankfurt, Germany
European Hematology Association (EHA)
June 7 - 10, 2023
-
Frankfurt, Germany
- PRESENTATION: Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial dostarlimab
- PRESENTATION: Biomarker correlates of response in patients with advanced Myxoid/Round Cell Liposarcoma (MRCLS) treated with NY-ES0-1 TCR T cells (Letetresgene autolueucel)
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
VYVGART is a registered trademark of argenx. VYVGART Hytrulo is a trademark of argenx.
© 2024 argenx MED-US-NON-2400036 v0.8 7/2024. All Rights Reserved.